Holen Sie sich die Stockscreener-App
31.41
4.38%
-1.44
Handel nachbörslich:
31.21
-0.20
-0.64%
Cue Biopharma Inc Aktie (CUE) Neueste Nachrichten
Cue Biopharma (CUE) Reports Hives Drug Results. Can Longer Relief Set it Apart? - Insider Monkey
Cue Biopharma, Inc. (CUE) Discusses Positive Phase II Top Line Results for CUE-221 in Chronic Spontaneous UrticariaSlideshow (NASDAQ:CUE) 2026-09-24 - Seeking Alpha
Cue Biopharma (CUE) Short Interest & Short Float | Updated Sep 2026 $CUE - MarketBeat
Lift Therapeutics Appoints Daniel Passeri as Chief Executive Officer - GlobeNewswire Inc.
China syndrome? Phase II wins for Cue in CSU, stock melts down - BioWorld News
Cue Biopharma stock swings after positive CUE-221 Phase 2 data and profit-taking - AD HOC NEWS
Cue Biopharma rated Buy after positive phase 2 results show superior efficacy in treating chronic spontaneous urticaria. - Pluang
Cue Biopharma: Initiating 'Buy' Based On CUE-221 Trial Win For CSU With Novel Dual MOA - Seeking Alpha
B. Riley's Buy Rating on Cue Biopharma (CUE) Highlights Market's High Price-to-Sales Expectations - GuruFocus
Cue Biopharma Announces Positive Phase 2 Results for CUE-221 in Chronic Spontaneous Urticaria - Kalkine Media
Cue Biopharma (CUE) Shares Drop 31% After Phase 2 Trial Results Despite Promising Efficacy - GuruFocus
Cue Biopharma plummets on phase 2 data for chronic spontaneous urticaria asset - Seeking Alpha
What's Going on With Cue Biopharma Stock on Monday? - benzinga.com
Cue Biopharma (CUE) Surges 41.7% Pre-Market Amid Market Rally an - GuruFocus
12 Health Care Stocks Moving In Monday's Pre-Market Session - benzinga.com
Cue Biopharma reports positive Phase 2 topline results for CUE-221 in CSU, durable benefit vs placebo and omalizumab - TradingView
Cue Biopharma Shares Jump 41.6% Premarket Following Phase 2 Trial Results - Yahoo Finance
Why is Cue Biopharma stock surging today? By Investing.com - Investing.com Canada
Cue Biopharma, Inc.(NasdaqCM: CUE) added to S&P Global BMI Index - marketscreener.com
Cue Biopharma (CUE) Reports Positive Phase 2 Data, Market Pricin - GuruFocus
Cue Biopharma reports positive phase 2 results for CUE-221 By Investing.com - Investing.com Canada
Cue Biopharma Reports Positive Phase 2 Topline Results for CUE-221 in Chronic Spontaneous Urticaria - Quiver Quantitative
Cue Biopharma Announces Positive Topline Results From Cue-221 Phase 2 Study In Chronic Spontaneous Urticaria - TradingView
Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria - GlobeNewswire
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Cue Biopharma, Inc. (NASDAQ: CUE) - Eastern Progress
Cue Biopharma (CUE) Stock Gains on B. Riley Buy Rating Amid High P/S Valuation - gurufocus.com
Cue Biopharma is a new Buy at B. Riley on valuation - TradingView
This Cue Biopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
CUE Initiated Coverage On by B. Riley Securities -- Price Target $83.00 - GuruFocus
Cue Biopharma Price Target Announced at $83.00/Share by B. Riley Securities - Moomoo
Cue Biopharma stock initiated at Buy by B.Riley on allergy drug potential - Investing.com Nigeria
Enterprise value to EBIT forward of Cue Biopharma, Inc. – SWB:1UC0 - TradingView
Cue Biopharma (CUE) Slides 8.21% to $28.00, Testing Support Near $26.60Volatility Skew - dars.gov.et
Cue Biopharma Inc (CUE) Financials FY2025: Revenue $27.5M, Net Loss $26.6M - Stock Titan
Shao-Lee Lin Discloses Investment at Cue Biopharma with 6.2% Stake - TradingView
Cue Biopharma (CUE) CEO builds stake with stock awards and cheap warrants - Stock Titan
Cue Biopharma, Inc. SEC Filing (Aug 21, 2026) - Stock Titan
Driehaus Capital Management Acquires New Stake in Cue Biopharma Inc (CUE) - GuruFocus
Cue Biopharma VP Michael Meluzio disposes of $169,323 in stock - Investing.com
Cue Biopharma VP Michael Meluzio disposes of $169,323 in stock By Investing.com - Investing.com South Africa
Cue Biopharma legal chief sells $265,627 in common stock - Investing.com
Cue Biopharma legal chief sells $265,627 in common stock By Investing.com - Investing.com Canada
Cue Biopharma (NASDAQ:CUE) VP Michael Vincent Meluzio Sells 5,628 Shares of Stock - MarketBeat
Insider Selling: Cue Biopharma (NASDAQ:CUE) Insider Sells $265,664.61 in Stock - MarketBeat
Cue Biopharma (NASDAQ: CUE) exec's tax sell-to-cover after equity grant - Stock Titan
Cue Biopharma (CUE) Q2 Results Highlight High Price-to-Sales Ami - GuruFocus
Cue Biopharma (CUE) Leaps 10.04% to $34.2, Testing Key Resistance at $35.91Seasonality Effect - Vinanet
CUE Stock Jumps Over 100% After Hours — What’s Driving The Rally? - Stocktwits
Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights - The Manila Times
Cue Biopharma (NASDAQ:CUE) Lowered to "Hold" Rating by Wall Street Zen - MarketBeat
Cue Biopharma CEO Lin sells shares worth $1.6 million By Investing.com - Investing.com Canada
Cue Biopharma CEO Lin sells shares worth $1.6 million - Investing.com
Insider Selling: Cue Biopharma (NASDAQ:CUE) CEO Sells $1,084,000.00 in Stock - MarketBeat
Insider Selling: Cue Biopharma (NASDAQ:CUE) CEO Sells 18,258 Shares - MarketBeat
Insider plans 58,258-share stock sale (NASDAQ: CUE) under Rule 144 - Stock Titan
Cue Biopharma (NASDAQ:CUE) Posts Quarterly Earnings Results, Misses Estimates By $22.45 EPS - MarketBeat
Cue Biopharma, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Cue Biopharma Q2 loss widens to $153.1M on non-cash charges - scanx.trade
Is Cue Biopharma Inc (CUE) Facing Financial Strain After Q2 Loss - GuruFocus
Cue Biopharma Q2 revenue more than doubles, net loss widens on one-time charges - TradingView
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):